Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27789777 | 0.88 | ULK1 (0.43) | JAK2JAK1ULK1 | |
| SCHEMBL16927747 | 0.88 | MCHR1 (0.40) | ENPP2MCHR1ULK1 | |
| SCHEMBL13129759 | 0.88 | MCHR1 (0.44) | ENPP2MCHR1ROCK2ROCK1LMNA | |
| SCHEMBL2806616 | 0.86 | MCHR1 (0.41) | ENPP2MCHR1LMNAMAPTMAPK1 | |
| SCHEMBL13129757 | 0.85 | MCHR1 (0.43) | ENPP2MCHR1LMNAMAPTMAPK1 | |
| SCHEMBL13129758 | 0.84 | ENPP2 (0.46) | ENPP2MCHR1 | |
| SCHEMBL16927752 | 0.82 | JAK2 (0.49) | JAK2JAK1ROCK2ULK1 | |
| SCHEMBL2810569 | 0.82 | MEN1 (0.47) | MCHR1LMNAMAPTMAPK1 | |
| SCHEMBL2806832 | 0.79 | JAK2 (0.44) | ENPP2JAK2JAK1ULK1 | |
| SCHEMBL13129773 | 0.78 | ENPP2 (0.41) | ENPP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240676-A1 | THIAZOLE DERIVATIVES | CCNE2, PKD1, PKD2 | ENPP2 4652/4885MCHR1 2362/4885JAK2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.